The Department of Endocrinology, 
Metabolic-Associated Fatty Liver Disease and Diabetes: A Double Whammy.
- Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, TN 632004, India
- Non communicable disease unit, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
- Department of Endocrinology, Bharti Hospital, Endocrine Society of India (ESI), Bharti Hospital & B.R.I.D.E, Karnal, India
- University Center for Research & Development, Chandigarh University, South Asian Federation of Endocrine Societies (SAFES), India. Electronic address: brideknl@gmail.com.
Endocrinology and metabolism clinics of North America Vol. 52 · Issue 3 · pp. 469-484
PMID 37495338 DOI 10.1016/j.ecl.2023.02.006
Cite This Article
Nitin Kapoor, Sanjay Kalra. Metabolic-Associated Fatty Liver Disease and Diabetes: A Double Whammy. Endocrinology and metabolism clinics of North America. 2023;52(3):469-484. doi:10.1016/j.ecl.2023.02.006
Abstract
Metabolic-associated fatty liver disease (MAFLD) is the hepatic manifestation of metabolic syndrome and affects about 55% of people living with diabetes. MAFLD has been shown to be an individual risk factor for cardiovascular disease and its associated mortality. Although common, MAFLD is often underdiagnosed and not given adequate attention during clinical visits. This review highlights the most recent literature available on the evaluation and management of MAFLD in the presence of diabetes. The more recently available antidiabetic agents including glucagon-like peptide-1 analogs and sodium-glucose cotransporter-2 inhibitors have been shown to effectively manage both diabetes and MAFLD.
Keywords
- Fatty liver
- Metabolic syndrome
- Metabolic-associated fatty liver disease
- Obesity
- Type 2 diabetes mellitus
